Quest

Analyst Nicholas Jansen set a price target at $116, pointing to expanding professional lab services, consumer-focused programs, and M&A as growth drivers.

The company beat the consensus Wall Street estimates on both the top and bottom lines. It also increased its EPS outlook for full-year 2017. 

The analysis from Quest Diagnostic researchers compared the cost-effectiveness of a seven-gene panel test to BRCA1 and BRCA2 testing alone in improving life expectancy.

In Williams v Quest/Athena, a federal district court judge has asked the highest state court to clarify if a genetic testing lab is a licensed healthcare provider.

The firms extended their OVA1 commercialization agreement an additional year while adding procedures for verifying the number of tests performed under the deal.

Veracyte said that Quest’s access to half of the physicians and hospitals in the US will provide patients with broader access to the Afirma GEC.

The company also announced a diagnostic laboratory service partnership with Montefiore Health System.

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

Judge Margaret Seymour held a hearing to better understand the facts of the case before deciding whether it should go forward.

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

Pages

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.